United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
Morgan Stanley Maintains Overweight on United Therapeutics, Lowers Price Target to $314
United Therapeutics Analyst Ratings
United Therapeutics Analyst Ratings
United Therapeutics (UTHR) Receives a Buy From Wedbush
Ladenburg Thalmann Maintains Buy on United Therapeutics, Raises Price Target to $268
Wedbush Lifts United Therapeutics' Price Target to $307 From $305 After 'Strong' Q2 Results, Keeps Outperform Rating
United Therapeutics Analyst Ratings
The Latest Analyst Ratings for United Therapeutics
Ladenburg Thalmann Adjusts Price Target on United Therapeutics to $256 From $285, Maintains Buy Rating
Ladenburg Thalmann Maintains Buy on United Therapeutics, Lowers Price Target to $256
H.C. Wainwright Sticks to Its Buy Rating for United Therapeutics (UTHR)
Argus Research Maintains Buy on United Therapeutics, Lowers Price Target to $280
UBS Trims Price Target on United Therapeutics to $310 From $330, Keeps Buy Rating
Morgan Stanley Maintains Overweight on United Therapeutics, Lowers Price Target to $316
Credit Suisse Lowers United Therapeutics' Price Target to $290 From $293, Maintains Outperform Rating
Morgan Stanley Maintains Overweight on United Therapeutics, Lowers Price Target to $320
Wedbush Sticks to Their Buy Rating for United Therapeutics (UTHR)
No Data